Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S ...

Mallinckrodt PLC, an Irish pharmaceutical company with a big footprint and long history in the St. Louis area, will buy U.S.

Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced it has entered into a definitive agreement to divest its ...

Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments.

Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.

Mallinckrodt plc ("Mallinckrodt") and Endo, Inc. (OTCQX: NDOI) ("Endo") today announced that they have entered into a definitive agreement to combine in a stock and cash transaction to create a global ...

The combination of Mallinckrodt and Endo will create a strong pharmaceutical company with a diversified portfolio, enhanced ...

Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after ...

Mallinckrodt and Endo , drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

Mallinckrodt and Endo, pharmaceutical companies that have each encountered business struggles, announced Thursday a $6.7 billion merger that they contend will result in a combined entity with the ...

Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced it has entered into a definitive agreement to divest its International Pharmaceuticals business, primarily operated through Canada ...